Shanghai Pioneer Holding Ltd

1345

KYG2162L1068

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
1.92 ^HKD	+2.13%		+2.67%	+4.92%

Mar. 26	Shanghai Pioneer Holding's 2023 Profit Falls as Revenue Stays Flat	MT
Mar. 25	Shanghai Pioneer Holding Ltd Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2023, Payable on 19 June 2024	CI

China Pioneer Pharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2019

March 27, 2020 at 10:56 am EDT

China Pioneer Pharma Holdings Limited announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 1,315.978 million compared to CNY 1,624.305 million a year ago. Net income was CNY 104.627 million compared to CNY 84.597 million a year ago. Basic earnings per share was CNY 0.09 compared to CNY 0.07 a year ago.

Latest news about Shanghai Pioneer Holding Ltd

Shanghai Pioneer Holding's 2023 Profit Falls as Revenue Stays Flat	Mar. 26	MT
Shanghai Pioneer Holding Ltd Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2023, Payable on 19 June 2024	Mar. 25	CI
Shanghai Pioneer Holding Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Shanghai Pioneer Holding Ltd Announces Management Changes, Effective 26 March 2024	Mar. 25	CI
Shanghai Pioneer's Unit Acquires Q3 Medical Devices' Intellectual Property Rights	Dec. 28	MT
Shanghai Pioneer Holding Ltd Announces Board Changes	23-10-12	CI
Shanghai Pioneer Holding Ltd Announces Change of Address of Registered Office	23-09-25	CI
Shanghai Pioneer Holding Ltd(SEHK:1345) dropped from S&P Global BMI Index	23-09-18	CI
Shanghai Pioneer Holding Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Shanghai Pioneer Holding Ltd Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on October 20, 2023	23-08-29	CI
Shanghai Pioneer Holding Ltd Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 15 June 2023	23-03-27	CI
Shanghai Pioneer Holding Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Shanghai Pioneer Sees 40% Rise in FY22 Profit	23-01-13	MT
Shanghai Pioneer Holding Ltd Provides Earnings Guidance for the Year Ended 31 December 2022	23-01-13	CI
Shanghai Pioneer Holding Unit to Inject 50 Million Yuan in Environmental Protection Company	22-12-09	MT
Shanghai Pioneer Holding Enters $69 Million Production Line Contracts	22-11-01	MT
China Pioneer Pharma Changes Name to Shanghai Pioneer Holding	22-10-26	MT
China Pioneer Pharma Holdings Limited has Changed its Name to Shanghai Pioneer Holding Ltd	22-10-24	CI
China Pioneer Pharma's H1 Profit Surges 78%	22-09-26	MT
Shanghai Pioneer Holding Ltd(SEHK:1345) added to S&P Global BMI Index	22-09-19	CI
China Pioneer Pharma Holdings Limited Announces Management Changes	22-09-16	CI
China Pioneer Pharma Holdings Limited Announces Resignation of Luo Chunyi as Chief Executive Officer	22-09-16	CI
China Pioneer Pharma Proposes Name Change; Shares Rally 14%	22-09-09	MT
China Pioneer Pharma Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 20 October 2022	22-08-31	CI
China Pioneer Pharma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI

Chart Shanghai Pioneer Holding Ltd

Duration

Period

More charts

Company Profile

Shanghai Pioneer Holding Ltd, formerly China Pioneer Pharma Holdings Ltd, is a China-based investment holding company mainly engaged in the marketing, promotion and sales of pharmaceutical products, medical devices and personal protective equipment. The Company operates mainly through three segments. The Products Sold via the Provision of Channel Management Services segment is principally engaged in the sales of the Company's ophthalmic pharmaceutical products to customers through pipeline management arrangements. The Products Sold via the Provision of Comprehensive Marketing, Promotion and Channel Management Services segment is principally engaged in the sale of all of the Company's pharmaceutical products and medical devices to customers through comprehensive marketing, promotion and channel management arrangements. The Sales of Personal Protective Materials segment is mainly engaged in the sales of personal protective materials include masks, protective gloves and protective suits.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SHANGHAI PIONEER HOLDING LTD	+4.92%	283M
MCKESSON CORPORATION	+13.36%	68.18B
CARDINAL HEALTH, INC.	+7.33%	25.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.34%	7.99B
SINOPHARM GROUP CO. LTD.	-2.79%	7.88B
HUADONG MEDICINE CO., LTD	-24.02%	7.62B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.83%	4.45B
EBOS GROUP LIMITED	-2.28%	3.89B
GALENICA AG	-3.51%	3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+25.02%	3.69B